Goldman Sachs Maintains Neutral on TransUnion, Lowers Price Target to $63

+3.74%

TransUnion

TRU

0.00

Goldman Sachs analyst Toni Kaplan maintains TransUnion (NYSE: TRU) with a Neutral and lowers the price target from $73 to $63.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

S&P Global (SPGI): Evaluating Valuation After New Compliance and Private Markets Product Launches

Can IonQ’s (IONQ) Quantum Networking Ambitions Redefine Its Competitive Edge After the Skyloom Deal?

RadNet (RDNT): Assessing Valuation After Recent 18% Share Price Rebound

Moog (MOG.A): Assessing Valuation After Recent 8% Share Price Rise

AvePoint (AVPT): Evaluating Valuation as AgentPulse Expands AI Security and Governance Capabilities

Does Zebra’s (ZBRA) Push Into AI and RFID Signal a New Era for Retail Technology Leadership?

Stock Ratings | BTIG maintained its "buy" recommendation for Cullinan Therapeutics (CGEM) stock and raised its price target from $32 to $38, representing a potential upside of 193.87%.

Canadian Consumer Debt Hits $2.6 Trillion as Mortgage Originations Surge, TransUnion Reports